Health and Fitness Health and Fitness
Tue, December 7, 2010
[ Tue, Dec 07th 2010 ] - Market Wire
Clinical Data from Two Phase II Studies Evaluatin .. Indolent Non-Hodgkina?s Lymphomas Presented at A
[ Tue, Dec 07th 2010 ] - Market Wire
Retrospective Analysis of Clinical Data from REVL .. 04) Reports a Significant Improvement in Survival
[ Tue, Dec 07th 2010 ] - Market Wire
Seattle Genetics and Millennium Report Positive D .. entuximab Vedotin (SGN-35) in Relapsed or Refract
[ Tue, Dec 07th 2010 ] - Market Wire
Pro-Pharmaceuticals Expands Patent Coverage to Australia
[ Tue, Dec 07th 2010 ] - Market Wire
Les donn©es de trois pr©sentations ©valuant le .. mide chez les patients atteints de my©lome multi
[ Tue, Dec 07th 2010 ] - Market Wire
Orthovita Receives FDA Clearance for Vitossa" Bioactive Foam-2X Bone Graft Substitute
[ Tue, Dec 07th 2010 ] - Market Wire
Affymax to Present at the Deutsche Bank 2010 BioFEST Conference
[ Tue, Dec 07th 2010 ] - Market Wire
Auf der Jahrestagung der US-amerikanischen Hmatol .. die klinischen Daten aus zwei Phase II-Studien z
[ Tue, Dec 07th 2010 ] - Market Wire
Exactech Announces Resolution of Government Investigation
[ Tue, Dec 07th 2010 ] - Market Wire
Wright Medical Group, Inc. Announces Initial Release of the PRO-TOEa" VO Hammertoe Fixation System
[ Tue, Dec 07th 2010 ] - Market Wire
Medtronic, Boston Scientific, St. Jude Medical, ZOLL Medical and Abiomed
[ Tue, Dec 07th 2010 ] - Market Wire
N. Anthony Coles, M.D. Named to LabCorp® Board of Directors
[ Tue, Dec 07th 2010 ] - Market Wire
ActiveHealth Management to Deliver Innovative NuV .. Nutritional Scoring System Through Health Website
[ Tue, Dec 07th 2010 ] - Market Wire
Pfizer, Merck, Amazon, eBay and Netflix
[ Tue, Dec 07th 2010 ] - Market Wire
La?Intergroupe Francophone du My©lome (IFM) a © .. de de phase III (IFM 2005 02), le traitement cont
[ Tue, Dec 07th 2010 ] - Market Wire
valuation, dans le cadre da?une ©tude de phase I .. , du traitement continu avec REVLIMID® de patien
[ Tue, Dec 07th 2010 ] - Market Wire
Il trattamento continuo con REVLIMID® per i pazi .. lo in seguito al trapianto autologo di cellule st
[ Tue, Dec 07th 2010 ] - Market Wire
CytRxa?s INNO-206 Safely Delivers High-Dose Doxor .. Human Tumors in Animal Model of Multiple Myeloma
[ Tue, Dec 07th 2010 ] - Market Wire
Pr©sentation l'ASH des donn©es cliniques de deu .. 'administration de REVLIMID® en association avec
[ Tue, Dec 07th 2010 ] - Market Wire
Geron Corporation Announces the Pricing of Its Public Offering of Common Stock
[ Tue, Dec 07th 2010 ] - Market Wire
La Jolla Pharmaceutical Company Announces Appoint .. nt of Dr. Bertrand C. Liang to Board of Directors
[ Tue, Dec 07th 2010 ] - Market Wire
Presentation at American Society of Hematology An .. ing Unfolded Protein Response is Promising Treatm
[ Tue, Dec 07th 2010 ] - Market Wire
Observational Study Demonstrates No Greater Incid .. Myeloid Leukemia with REVLIMID® in Patients with
[ Tue, Dec 07th 2010 ] - Market Wire
L'analyse r©trospective des donn©es cliniques d .. r le REVLIMID®(MDS-004) signale une am©lioratio
[ Tue, Dec 07th 2010 ] - Market Wire
Ex-post-Analyse der klinischen Daten von REVLIMID .. ergibt, dass sich die berlebensrate von Patienten
[ Tue, Dec 07th 2010 ] - Market Wire
Retrospectieve analyse van klinische gegevens uit .. LIMID (MDS-004) laat belangrijke verbetering zien
[ Tue, Dec 07th 2010 ] - Market Wire
Targacept to Present at 2010 Deutsche Bank BioFEST
[ Tue, Dec 07th 2010 ] - Market Wire
Data from Three Presentations Evaluating Clinical .. reviously Treated Multiple Myeloma Presented at A
[ Tue, Dec 07th 2010 ] - Market Wire
REVLIMID®-Daten von Patienten mit multiplem Myel .. nsraten mit niedrig und hoch dosiertem Dexamethas
[ Tue, Dec 07th 2010 ] - Market Wire
Presentazione all'ASH dei dati derivati da tre pr .. e dei benefici clinici del pomalidomide nel mielo

Presentazione all'ASH dei dati derivati da tre presentazioni per la valutazione dei benefici clinici del pomalidomide nel mielo


Published on 2010-12-07 12:05:19 - Market Wire
  Print publication without navigation


BOUDRY, Svizzera--([ BUSINESS WIRE ])--Celgene International Srl (NASDAQ: CELG) ha annunciato oggi la valutazione del suo prossimo composto IMiD® il pomalidomide, in tre diversi studi sperimentali di pazienti affetti da mieloma multiplo recidivante o refrattario in seguito a trattamenti precedenti a base di lenalidomide, talidomide e bortezomib. I dati clinici sono stati presentati in occasione del 52 incontro annuale della Societ Americana di Ematologia (ASH) a Orlando, in Florida.

Compendio n. 859 a" Studio di Fase 2 di 2 modalit di pomalidomide (CC4047) pi una dose ridotta di desametasone come terapia per il mieloma multiplo recidivante, IFM 2009-02

Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al testo in lingua originale, che l'unico giuridicamente valido.

Contributing Sources